Drug Profile
PF 06821497
Alternative Names: PF-06821497Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Isoquinolines; Pyridines; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
- No development reported Follicular lymphoma; Small cell lung cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Follicular lymphoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Follicular lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Russia (PO)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Follicular lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO)